2. Establishment of Risk & Compliance Dept. and dissolution of Sustainability Dept.

In order to enhance the governance, Chugai will integrate the risk management and compliance promotion functions (including information management), which have been distributed within the company, to improve the effectiveness and efficiency. Organizational reforms of the corporate functions will be in place, including the establishment of Risk & Compliance Dept. and the dissolution of Sustainability Dept. Human Resources Management Dept. will be responsible for environmental protection and other EHS initiatives that have been driven by Sustainability Dept. At the same time, Chugai will continue its company-wide efforts for sustainability.

• Risk & Compliance Dept. will be newly established.
• Sustainability Dept. will be dissolved.
• The risk management and compliance promotion functions will be transferred to Risk & Compliance Dept. from General Affairs Dept., Sustainability Dept., Legal Dept., Business Strategy & Compliance Dept., and Corporate Planning Dept.
• Sustainability Dept.’s functions will be transferred: the EHS function to Human Resources Management Dept., and the social contribution function to General Affaires Dept.

3. Reorganization of Research Div.

The company will conduct organizational reforms to improve the success rate of drug discovery and the research productivity. The reforms aim to clarify the scope of responsibilities in accordance with technology areas and to enhance drug discovery technologies and digital infrastructures, as well as dealing with the diversification of approaches for drug discovery. For this purpose, Modality Technology Dept. and Biological Technology Dept. will be established, and Discovery Technology Dept. will be dissolved.

• Modality Technology Dept. will be newly established.
• Biological Technology Dept. will be newly established.
• Discovery Technology Dept. will be dissolved.

4. Reorganization of Translational Research Div. and Research Div.

The name and missions of Non-clinical Safety Assessment Dept. of Translational Research Div. will be changed to pursue a high-level human prediction, in addition to existing responsibilities that includes safety research, drug discovery research and integrated safety risk assessments with clinical and non-clinical information. Non-clinical Safety Assessment Dept. will be renamed Safety and Bioscience Research Dept., and its pharmacology documentation function will be transferred to Discovery Pharmacology Dept. of Research Div.

• Non-clinical Safety Assessment Dept. will be renamed Safety and Bioscience Research Dept.
• The pharmacology documentation function of Non-clinical Safety Assessment Dept. will be transferred to Discovery Pharmacology Dept. of Research Div.

5. Reorganization of Medical Affairs Div.

In order to realize more advanced and specialized Medical Affairs (MA) functions including evidence generation activities, the company integrated Medical Liaison Dept. and Medical Science Dept. Also, organizational changes will be implemented to enable the planning and execution of medical strategies by specialized areas. Oncology Medical Science Dept. and Specialty Medical Science Dept. will be established while Medical Science Dept. and Medical Liaison Dept. will be dissolved. In addition, the medical information provision management functions that have been dispersed across multiple organizations will be integrated in Medical Information Dept.

• Oncology Medical Science Dept. will be newly established.
• Specialty Medical Science Dept. will be newly established.
• Medical Science Dept. will be dissolved.
• Medical Liaison Dept. will be dissolved.
• The medical information provision management functions will be integrated in Medical Information Dept.

[Details of Personnel Changes]

Directors

Executive Officers

Please see the PDF file about other personnel changes.